RESEARCH ARTICLE

KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma

  • Shi Wei 1 ,
  • Miaomiao Dai 1 ,
  • Chi Zhang 1 ,
  • Kai Teng 2 ,
  • Fengwei Wang 1 ,
  • Hongbo Li 3 ,
  • Weipeng Sun 4 ,
  • Zihao Feng 5 ,
  • Tiebang Kang 1 ,
  • Xinyuan Guan 6 ,
  • Ruihua Xu 1 ,
  • Muyan Cai , 1,7 ,
  • Dan Xie , 1,7
Expand
  • 1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
  • 2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250200, China
  • 3. Department of Musculoskeletal Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
  • 4. Department of Anorectal Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 510370, China
  • 5. Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
  • 6. Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
  • 7. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

Received date: 22 Feb 2020

Accepted date: 28 Jun 2020

Published date: 15 Oct 2021

Copyright

2020 The Author(s)

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is the fourth-leading cause of cancer-related deaths worldwide. HCC is refractory to many standard cancer treatments and the prognosis is often poor, highlighting a pressing need to identify biomarkers of aggressiveness and potential targets for future treatments. Kinesin family member 2C (KIF2C) is reported to be highly expressed in several human tumors. Nevertheless, the molecular mechanisms underlying the role of KIF2C in tumor development and progression have not been investigated. In this study, we found that KIF2C expression was significantly upregulated in HCC, and that KIF2C up-regulation was associated with a poor prognosis. Utilizing both gain and loss of function assays, we showed that KIF2C promoted HCC cell proliferation, migration, invasion, and metastasis both in vitro and in vivo. Mechanistically, we identified TBC1D7 as a binding partner of KIF2C, and this interaction disrupts the formation of the TSC complex, resulting in the enhancement of mammalian target of rapamycin complex1 (mTORC1) signal transduction. Additionally, we found that KIF2C is a direct target of the Wnt/β-catenin pathway, and acts as a key factor in mediating the crosstalk between Wnt/β-catenin and mTORC1 signaling. Thus, the results of our study establish a link between Wnt/β-catenin and mTORC1 signaling, which highlights the potential of KIF2C as a therapeutic target for the treatment of HCC.

Cite this article

Shi Wei , Miaomiao Dai , Chi Zhang , Kai Teng , Fengwei Wang , Hongbo Li , Weipeng Sun , Zihao Feng , Tiebang Kang , Xinyuan Guan , Ruihua Xu , Muyan Cai , Dan Xie . KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma[J]. Protein & Cell, 2021 , 12(10) : 788 -809 . DOI: 10.1007/s13238-020-00766-y

1
Ally A, Balasundaram M, Carlsen R, Chuah E, Clarke A, Dhalla N, Holt RA, Jones SJM, Lee D, Ma Y (2017) Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169:1327

DOI

2
Bhat M, Sonenberg N, Gores GJ (2013) The mTOR pathway in hepatic malignancies. Hepatology 58:810–818

DOI

3
Bie L, Zhao G, Wang YP, Zhang B (2012) Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas. Clin Neurol Neurosurg 114:356–360

DOI

4
Braun A, Dang K, Buslig F, Baird MA, Davidson MW, Waterman CM, Myers KA (2014) Rac1 and Aurora A regulate MCAK to polarize microtubule growth in migrating endothelial cells. J Cell Biol 206:97–112

DOI

5
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

DOI

6
Capo-Chichi JM, Tcherkezian J, Hamdan FF, Decarie JC, Dobrzeniecka S, Patry L, Nadon MA, Mucha BE, Major P, Shevell M (2013) Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly. J Med Genet 50:740–744

DOI

7
Chang CY, Lin SC, Su WH, Ho CM, Jou YS (2012) Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma. Oncogene 31:2640–2652

DOI

8
Chen JX, Rajasekaran M,Xia HP, Zhang XQ, Kong SN, Sekar K, Seshachalam VP, Deivasigamani A, Goh BKP, Ooi LL (2016) The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/beta-catenin signalling pathway. Gut 65:1522–1534

DOI

9
Chen JL, Li S, Zhou S, Cao SJ, Lou Y, Shen HY, Yin J, Li G (2017) Kinesin superfamily protein expression and its association with progression and prognosis in hepatocellular carcinoma. J Cancer Res Ther 13:651–659

DOI

10
Choi YJ, Park YJ, Park JY, Jeong HO, Kim DH, Ha YM, Kim JM, Song YM, Heo HS, Yu BP (2012) Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion. PLoS ONE 7:e43418

DOI

11
Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149:1192–1205

DOI

12
Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, Murphy LO, Manning BD (2012) TBC1D7 Is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell 47:535–546

DOI

13
Eichenlaub-Ritter U (2015) Microtubule dynamics and tumor invasion involving MCAK. Cell Cycle 14:3353

DOI

14
El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 340:745–750

DOI

15
Gan HZ, Lin L, Hu NJ, Yang Y, Gao Y, Pei Y, Chen K, Sun BT (2019) KIF2C exerts an oncogenic role in nonsmall cell lung cancer and is negatively regulated by miR-325-3p. Cell Biochem Funct 37:424–431

DOI

16
Gonsalves FC, Klein K, Carson BB, Katz S,Ekas LA, Evans S, Nagourney R, Cardozo T, Brown AM, DasGupta R (2011) An RNAi-based chemical genetic screen identifies three smallmolecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci USA 108:5954–5963

DOI

17
Grandy D, Shan JF, Zhang XX, Rao S, Akunuru S, Li HY, Zhang YH, Alpatov I,Zhang XA, Lang RA (2009) Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 284:16256–16263

DOI

18
Gulhati P, Bowen KA, Liu J,Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL,O’Connor KL, Gao T (2011) mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 71:3246–3256

DOI

19
Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y, Zhang Y, Han L (2018) TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex. Oncogene 37:478–488

DOI

20
Harris TE, Lawrence JC Jr (2003) TOR signaling. Sci STKE 2003:15

DOI

21
Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS (1997) Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 185:82–91

DOI

22
Hirokawa N, Noda Y, Tanaka Y, Niwa S (2009) Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol 10:682–696

DOI

23
Honnappa S, Gouveia SM, Weisbrich A, Damberger FF, Bhavesh NS, Jawhari H, Grigoriev I,van Rijssel FJA, Buey RM, Lawera A (2009) An EB1-binding motif acts as a microtubule tip localization signal. Cell 138:366–376

DOI

24
Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55–61

DOI

25
Huang SMA, Mishina YM, Liu SM, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461:614–620

DOI

26
Huang Y, Wang H, Lian Y, Wu X, Zhou L, Wang J, Deng M, Huang Y (2018) Upregulation of kinesin family member 4A enhanced cell proliferation via activation of Akt signaling and predicted a poor prognosis in hepatocellular carcinoma. Cell Death Dis 9:141

DOI

27
Ince N, Wands JR (1999) The increasing incidence of hepatocellular carcinoma. New Engl J Med 340:798–799

DOI

28
Inoki K, Corradetti MN, Guan KL (2005) Dysregulation of the TSCmTOR pathway in human disease. Nat Genet 37:19–24

DOI

29
Inoki K,Ouyang H, Zhu TQ, Lindvall C, Wang Y, Zhang XJ, Yang Q, Bennett C, Harada Y, Stankunas K (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955–968

DOI

30
Ishikawa K, Kamohara Y, Tanaka F, Haraguchi N, Mimori K, Inoue H, Mori M (2008) Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer. Br J Cancer 98:1824–1829

DOI

31
Jacinto E, Hall MN (2003) Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117–126

DOI

32
Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM (2018) Role of Wnt/beta-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma 5:61–73

DOI

33
Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW (2012) Wntpathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18:4997–5007

DOI

34
Lee T, Langford KJ, Askham JM, Bruning-Richardson A, Morrison EE (2008) MCAK associates with EB1. Oncogene 27:2494–2500

DOI

35
Li H, Shen S, Chen X, Ren Z, Li Z, Yu Z (2019a) miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway. Cancer Cell Int 19:205

DOI

36
Li Q, Pan XX, Zhu DM, Deng ZM, Jiang RQ, Wang XH (2019b) Circular RNA MAT2B promotes glycolysis and malignancy of hepatocellular carcinoma through the miR-338-3p/PKM2 axis under hypoxic stress. Hepatology 70:1298–1316

DOI

37
Li Q, Qiu J, Yang H, Sun G, Hu Y, Zhu D, Deng Z, Wang X, Tang J, Jiang R (2020) Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma. Cancer Lett 482:112–125

DOI

38
Luo W, Liao M, Liao Y, Chen X, Huang C,Fan J, Liao W (2018) The role of kinesin KIF18A in the invasion and metastasis of hepatocellular carcinoma. World J Surg Oncol 16:36

DOI

39
Mamane Y, Petroulakis E, Rong LW, Yoshida K, Ler LW, Sonenberg N (2004) eIF4E—from translation to transformation. Oncogene 23:3172–3179

DOI

40
Matter MS, Decaens T, Andersen JB, Thorgeirsson SS (2014) Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends . J Hepatol 60:855–865

DOI

41
Moore AT, Rankin KE, von Dassow G, Peris L, Wagenbach M, Ovechkina Y, Andrieux A, Job D, Wordeman L (2005) MCAK associates with the tips of polymerizing microtubules. J Cell Biol 169:391–397

DOI

42
Nakamura Y, Tanaka F, Haraguchi N, Mimori K, Matsumoto T, Inoue H, Yanaga K, Mori M (2007) Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. Br J Cancer 97:543–549

DOI

43
Njei B, Rotman Y, Ditah I, Lim JK (2015) Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 61:191–199

DOI

44
Pez F,Lopez A, Kim M,Wands JR, de Fromentel CC, Merle P (2013) Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol 59:1107–1117

DOI

45
Ritter A, Sanhaji M, Friemel A, Roth S, Rolle U, Louwen F, Yuan JP (2015) Functional analysis of phosphorylation of the mitotic centromere-associated kinesin by Aurora B kinase in human tumor cells. Cell Cycle 14:3755–3767

DOI

46
Ritter A, Kreis NN, Louwen F, Wordeman L, Yuan JP (2016) Molecular insight into the regulation and function of MCAK. Crit Rev Biochem Mol 51:228–245

DOI

47
Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun ZT, Tang ZY, Qin LX (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70:10202–10212

DOI

48
Saucedo LJ, Gao XS, Chiarelli DA, Li L, Pan D, Edgar BA (2003) Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol 5:566–571

DOI

49
Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168:960–976

DOI

50
Shimo A, Tanikawa C, Nishidate T, Lin ML, Matsuda K, Park JH, Ueki T, Ohta T, Hirata K, Fukuda M (2008) Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci 99:62–70

DOI

51
Tanaka S, Arii S (2012) Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 39:486–492

DOI

52
Tanenbaum ME, Medema RH, Akhmanova A (2011) Regulation of localization and activity of the microtubule depolymerase MCAK. Bioarchitecture 1:80–87

DOI

53
Teng K, Wei S, Zhang C, Chen JW, Chen JB, Xiao KH, Liu J, Dai MM, Guan XY, Yun JP (2019) KIFC1 is activated by TCF-4 and promotes hepatocellular carcinoma pathogenesis by regulating HMGA1 transcriptional activity. J Exp Clin Cancer Res 38:329

DOI

54
Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C,Tovar V, Roayaie S, Minguez B, Sole M (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135:1972–1983

DOI

55
Zhang Y, Gao XS, Saucedo LJ, Ru BG, Edgar BA, Pan DJ (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578–581

DOI

56
Zhang GP, Shen SL, Yu Y, Yue X, Hu WJ, Li SQ (2020) Kinesin family member 2C aggravates the progression of hepatocellular carcinoma and interacts with competing endogenous RNA. J Cell Biochem.https://doi.org/10.1002/jcb.29665

DOI

57
Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, Bian XW, Lin MC, Kung HF, Zeng YX (2012) Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition. Gut 61:562–575

DOI

Outlines

/